Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Mikala · SciRah

Researcher profile · Semantic Scholar

G. Mikala

Share profile

G. Mikala — researcher profile on SciRah

h-index: 32
Works: 271
Citations: 4,092

Most-cited papers

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
M. Dimopoulos, V. Hungria, A. Radinoff, S. Delimpasi +22 more
2023The Lancet Haematology110 citations
Semantic Scholar
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
M. Dimopoulos, P. Voorhees, F. Schjesvold, Y. Cohen +32 more
2024New England Journal of Medicine79 citations
Semantic Scholar
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
Zachary D. Crees, M. Rettig, R. Jayasinghe, K. Stockerl-Goldstein +28 more
2023Nature Medicine67 citations Open access
Semantic Scholar
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
F. Schjesvold, M. Dimopoulos, S. Delimpasi, P. Robak +24 more
2022The Lancet Haematology62 citations Open access
Semantic Scholar
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
V. Urbán, A. Ceglédi, G. Mikala
2022GeroScience30 citations Open access
Semantic Scholar
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
L. Kotmayer, T. László, G. Mikala, R. Kiss +24 more
2023International Journal of Molecular Sciences26 citations Open access
Semantic Scholar
Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL)
Attila Kállai, Z. Ungvari, M. Fekete, Andrea B. Maier +3 more
2024GeroScience23 citations Open access
Semantic Scholar
Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy
Andrea Lehoczki, M. Fekete, G. Mikala, I. Bodó
2024GeroScience18 citations Open access
Semantic Scholar
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
V. Szita, G. Mikala, A. Kozma, J. Fábián +11 more
2022Pathology and Oncology Research16 citations Open access
Semantic Scholar
The Effect of Belantamab Mafodotin on Primary Myeloma–Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells
Zsolt Matula, F. Uher, I. Vályi-Nagy, G. Mikala
2023International Journal of Molecular Sciences15 citations Open access
Semantic Scholar
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Ákos Nagy, B. Bátai, L. Kiss, Stefánia Gróf +22 more
2023Journal of Internal Medicine12 citations Open access
Semantic Scholar
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.
M. Beksaç, I. Špička, R. Hájek, S. Bringhen +8 more
2022Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis12 citations Open access
Semantic Scholar
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
I. Avivi, D. Vesole, J. Dávila-Valls, L. Usnarska-Zubkiewicz +26 more
2023Cancers11 citations Open access
Semantic Scholar
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
K. Weisel, V. Hungria, A. Radinoff, S. Delimpasi +14 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria
Austin G. Kulasekararaj, Anna-Elina Lehtinen, C. Forsyth, Shreyans Gandhi +17 more
2023Haematologica10 citations Open access
Semantic Scholar
Prognostic impact of a senescence gene signature in multiple myeloma
Andrea Lehoczki, O. Menyhárt, H. Andrikovics, M. Fekete +4 more
2025GeroScience7 citations Open access
Semantic Scholar
Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study
Anita Marx, M. Osváth, B. Szikora, O. Pipek +10 more
2023PLoS ONE7 citations Open access
Semantic Scholar
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
F. Takács, L. Kotmayer, Á. Czeti, Gábor Szalóki +15 more
2022Pathology and Oncology Research7 citations Open access
Semantic Scholar
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
L. Pour, I. Micheva, G. Usenko, G. Mikala +7 more
2024Clinical Lymphoma, Myeloma & Leukemia6 citations Open access
Semantic Scholar
Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy—Analysis of 130 Eyes of 65 Subjects
Kitti Kormányos, Klaudia Kovács, Orsolya Németh, Gábor Tóth +10 more
2022Journal of Clinical Medicine6 citations Open access
Semantic Scholar
Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial
Zachary D. Crees, K. Stockerl-Goldstein, Sarah M. Larson, Á. Illés +21 more
2021Blood6 citations Open access
Semantic Scholar
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
A. Ceglédi, Z. Csukly, M. Fekete, A. Kozma +3 more
2023Pathology oncology research : POR5 citations Open access
Semantic Scholar
Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
V. Hungria, K. Weisel, A. Radinoff, S. Delimpasi +19 more
2023Blood5 citations Open access
Semantic Scholar
Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol
A. Ceglédi, Á. Bátai, J. Dolgos, M. Fekete +9 more
2024Pathology oncology research : POR4 citations Open access
Semantic Scholar
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
M. Dimopoulos, F. Schjesvold, Cheng-Cheng Fu, M. Hartley-Brown +43 more
2026The Lancet3 citations Open access
Semantic Scholar
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
Paul G. Richardson, F. Schjesvold, Cheng-Cheng Fu, M. Hartley-Brown +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, M. Dimopoulos, Y. Cohen, F. Schjesvold +35 more
2025Blood3 citations
Semantic Scholar
Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
M. Dimopoulos, P. Voorhees, F. Schjesvold, Y. Cohen +30 more
2024Blood3 citations
Semantic Scholar
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
S. Lovas, Nóra Obajed Al-Ali, G. Varga, V. Szita +7 more
2022Pathology and Oncology Research3 citations Open access
Semantic Scholar
Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review
A. Ceglédi, Ágnes Király, Andrea Várkonyi, Szabolcs Tasnády +9 more
2024Pharmaceuticals2 citations Open access
Semantic Scholar
S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)
M. Dimopoulos, V. Hungria, A. Radinoff, S. Delimpasi +14 more
2023HemaSphere2 citations Open access
Semantic Scholar
OA-29 First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma
Jonathan L. Kaufman, Cristina J. Gasparetto, Tibor Kovacsovics, G. Mikala +13 more
2023Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
A. Ceglédi, J. Dolgos, M. Fekete, L. Gopcsa +4 more
2023Pathology and Oncology Research2 citations Open access
Semantic Scholar
Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
F. Schjesvold, M. Dimopoulos, S. Delimpasi, P. Robak +20 more
2023Blood2 citations Open access
Semantic Scholar
Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement
Nikolett Lupsa, Ákos Szegedi, A. Gézsi, Zoltán Vuncs +8 more
2022Biomedicines2 citations Open access
Semantic Scholar
MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
T. Facon, P. Moreau, T. Martin, I. Špička +12 more
20212 citations
Semantic Scholar
Myelomaújdonságok az ASH 2024-en
Gergely Varga, G. Mikala
2025Hematológia−Transzfuziológia1 citations
Semantic Scholar
Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients – Real World Data from Hungary
S. Lovas, Nora Obajed Al-Ali, K. Farkas, L. Pinczés +7 more
2025Journal of Hematology1 citations Open access
Semantic Scholar
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis
Hermina Sánta, Laura Regáli, L. Váróczy, V. Szita +16 more
2025Journal of Clinical Medicine1 citations
Semantic Scholar
P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
V. Hungria, K. Weisel, A. Radinoff, S. Delimpasi +20 more
2024Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study
Zachary D. Crees, M. Rettig, R. Jayasinghe, K. Stockerl-Goldstein +28 more
2024Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma
A. Bors, A. Kozma, Ágnes Tomán, Z. Őrfi +6 more
2024Cancers1 citations Open access
Semantic Scholar
Myeloma multiplex a 2023-as ASH-kongresszuson
Gergely Varga, G. Mikala
2024Hematológia−Transzfuziológia1 citations
Semantic Scholar
Miért szelektál a lenalidomid alkalmazása TP53 diszfunkció irányában?
András Kozma, G. Mikala
2023Hematológia−Transzfuziológia1 citations
Semantic Scholar
Az idősödés során jellemző genetikai és epigenetikai változások és a gammopátiák progressziója •
S. Urbán, László Kocsis, G. Mikala
2023Hematológia−Transzfuziológia1 citations
Semantic Scholar
["When it rains, it pours" - de novo diagnosed multiple myeloma with invasive Streptococcus pneumoniae infection in severe COVID-19 complicated with cytokine storm].
Dorina Korózs, Nóra Jenőfi, Bálint Szabó, János Szlávik +1 more
2023Orvosi Hetilap1 citations Open access
Semantic Scholar
Evaluation of Retinal Blood Flow in Patients with Monoclonal Gammopathy Using OCT Angiography
C. Czakó, Dóra Gerencsér, Kitti Kormányos, Klaudia Kéki-Kovács +11 more
2023Journal of Clinical Medicine1 citations Open access
Semantic Scholar
Az őssejt-mobilizáció aktualitásai myeloma multiplexben
Zsuzsanna Szemlaky, A. Ceglédi, G. Mikala
2023Hematológia−Transzfuziológia1 citations
Semantic Scholar
Gaucher-kór és az ajánlott új diagnosztikai algoritmus
Ottó Csacsovszki, Hussain Alizadeh, Árpád Bátai, G. Kriván +4 more
2023Hematológia−Transzfuziológia1 citations Open access
Semantic Scholar
IBCL-222 Parallel Testing of Liquid Biopsy (ctDNA) and Tissue Biopsy Samples Yields Higher Frequency of EZH2 Mutations in Follicular Lymphoma.
Ákos Nagy, B. Bátai, Stefánia Gróf, L. Kiss +9 more
2022Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Hungria×10
Invite
V. Hungria — researcher profile on SciRah
S. Delimpasi×7
Invite
S. Delimpasi — researcher profile on SciRah
Tamás Masszi×7
Invite
Tamás Masszi — researcher profile on SciRah
I. Špička×7
Invite
I. Špička — researcher profile on SciRah

×7

Invite

T. Masszi — researcher profile on SciRah

Invite

G. Varga — researcher profile on SciRah

Invite

K. Weisel — researcher profile on SciRah

Invite

M. Plander — researcher profile on SciRah

Invite

M. Fekete — researcher profile on SciRah

Invite

A. Radinoff — researcher profile on SciRah

Invite

Mary Li — researcher profile on SciRah

F. Schjesvold×5

Invite

F. Schjesvold — researcher profile on SciRah